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Abstract
Chromosomal translocations play a crucial role in tumorigenesis, often resulting in the formation
of chimeric genes or in gene deregulation through position effects. T-cell acute lymphoblastic
leukemia (T-ALL) is associated with a large number of such rearrangements. We report the ectopic
expression of the 3' portion of EST DA926692 in the bone marrow of a childhood T-ALL case
showing a t(2;11)(q11.2;p15.1) translocation as the sole chromosome abnormality. The
breakpoints, defined at the sequence level, mapped within HPS5 (Hermansky Pudlak syndrome 5)
intron 1 at 11p15.1, and DA926692 exon 2 at 2q11.2. The translocation was accompanied by a
submicroscopic inversion that brought the two genes into the same transcriptional orientation. No
chimeric trancript was detected. Interestingly, Real-Time Quantitative (RQ)-PCR detected, in the
patient's bone marrow, expression of a 173 bp product corresponding to the 3' portion of
DA926692. Samples from four T-ALL cases with a normal karyotype and normal bone marrow
used as controls were negative. It might be speculated that the juxtaposition of this genomic
segment to the CpG island located upstream HPS5  activated  DA92669  expression. RQ-PCR
analysis showed expression positivity in 6 of 23 human tissues examined. Bioinformatic analysis
excluded that this small non-coding RNA is a precursor of micro-RNA, although it is conceivable
that it has a different, yet unknown, functional role. To the best of our knowledge, this is the first
report, in cancer, of the activation of a small non-coding RNA as a result of a chromosomal
translocation.
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Findings
Acquired balanced chromosomal translocations provide
crucial diagnostic and prognostic data in cancer patients.
They are probably pathogenetically significant as initiat-
ing events if present as the only cytogenetic changes [1].
These rearrangements often result in the formation of a
fusion gene, encoding a chimeric oncogenic protein, or in
the deregulation of the expression pattern of genes flank-
ing the breakpoint regions by promoter swapping [1-3].
Overall, gene deregulation can be accomplished through
position effects, such as a gene juxtaposition close to an
active chromatin domain. More rarely, translocations may
result in gene downregulation because of hypermethyla-
tion of CpG islands at the breakpoint [4], or in the forma-
tion of chimeric transcripts that do not encode for a
protein with oncogenic potential [5].
T-ALL, as other hematological malignancies, is associated
with a number of chromosomal abnormalities, resulting
either in a position effect or in a gene fusion [6].
Here we report the cloning of a novel balanced
t(2;11)(q11.2;p15.1) translocation, found as the sole
cytogenetic abnormality in the BM of a childhood T-ALL
case, accompanied by the ectopic expression of the 3' por-
tion of EST DA926692.
A 14-year-old male patient was referred to our hospital for
rhinolalia. Total body CT disclosed a diffuse enlargement
of the rhinopharynx vault, lymphoid hyperplasia of the
Waldeyer's tonsillar ring, and a mediastinal enlargement.
BM aspiration showed 90% of blast cells. Flow cytometry
revealed that blast cell population was positive for CD 45,
2, 5, 7, and cytoplasmic CD3, while negative for CD1a
and surface CD3. These findings were consistent with a
diagnosis of early T-ALL, thus the patient started treatment
based on AIEOP-BFM ALL 2000 protocol [7].
At the end of induction therapy, the patient was catego-
rized as "high risk" due to incomplete remission, as per
protocol stratification criteria. After consolidation ther-
apy, the BM aspirate showed no haematological remis-
sion, so treatment continued following the AIEOP LLA
REC 2003 protocol and complete hematological remis-
sion was obtained.
One year from diagnosis, the patient underwent HLA-
identical hematopoietic stem cell transplantation from an
unrelated donor. He is now doing well and is still in
hematologic remission.
G-banding analysis of bone marrow metaphases at onset
revealed the karyotype 46,XY,t(2;11)(q11.2;p15.1) [27]
[8] (Fig. 1A). FISH analysis excluded the presence of
known rearrangements (data not shown), and revealed
that the chromosome 11 breakpoint was encompassed by
the BAC clone RP11-320K10 (chr11:18,229,291–
18,413,758) and the fosmid G248P8335B2 (Fig. 1B), har-
boring the 5' UTR regions of two genes, HPS5  and
GTF2H1, located 422 bp apart and in opposite transcrip-
tional orientation (Fig. 1F).
The break on chromosome 2 was mapped within the
interval chr2:96,884,868–97,812,993, delimited by the
BACs RP11-1141J14 (chr2:96,884,868–97,038,565) and
RP11-716G6 (chr2:97,631,541–97,812,993) at 2q11.2,
yielding FISH signals on der(2) and der(11), respectively
(Figs. 1B,C). It was not possible to further refine this
breakpoint region by large-insert probes, as it is almost
entirely composed of segmental duplications. We identi-
fied two small regions devoid of duplicons:
chr2:97,284,347–97,296,849 (12,503 bp) and
chr2:97,379,383–97,391,787 (12,405 bp) (Figure 1E).
We obtained a long-range PCR product from the latter
interval, that appeared to encompass the breakpoint on
chromosome 2 (Figure 1D,E). This conclusion, however,
was regarded with caution, since the region is rich in copy
number variants (UCSC, Structural Variation track) pro-
viding a possible alternative explanation for the FISH
results. The amplified interval does not contain known
genes, although a number of ESTs of unknown function
are annotated (Fig. 1E).
Vectorette-PCR using a reverse primer (hpsgtf-R, Table 1),
specific for the genomic segment between genes HPS5 and
GTF2H1, produced a fragment of approximately 800 bp.
The sequence (Accession No. EU617360) showed that
chromosome 11 at nt 18,300,006 (HPS5 intron 1) was
fused with chromosome 2 at nt 97,384,504 (EST
DA926692  exon 2) (Fig. 1G). Unexpectedly, sequences
from chromosomes 2 and 11 had the same orientation.
The same approach was used to clone the reciprocal
genomic fusion DA926692/HPS5. Vectorette PCR with a
forward primer (hps5-F, Table 1) designed within HPS5
intron 1 yielded a fragment of 1,050 bp. The sequence
(Accession No. EU617359) revealed that chromosome 2,
at nt 97,384,507 (DA926692  exon 2), was fused with
chromosome 11 at nt 18,299,998 (HPS5 intron 1) (Fig.
1H). Again, sequences from the two chromosomes had
the same orientation. These observations clearly suggested
that one of the two sequences had undergone a submicro-
scopic inversion before translocation. As a consequence,
DA926692 and HPS5 were brought, by the inversion, into
the same orientation.
5'- and 3'-RACE-PCR as well as RT-PCR experiments,
aimed at cloning possible HPS5/DA926692 chimeric tran-
scripts, failed.Molecular Cancer 2008, 7:80 http://www.molecular-cancer.com/content/7/1/80
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Further RQ-PCR analyses aiming at quantifying the
expression levels of genes flanking the breakpoints, i.e.
HPS5 (Fig. 2A) and GTF2H1 (data not shown) on chro-
mosome 11, and ANKRD36, FAHD2B, KIAA1641, ZAP70
on chromosome 2, revealed no misexpression in the
present case compared to other T-ALL cases without the
t(2;11) translocation (data not shown).
The same approach was used for DA926692. A primer set
specific for exon 1, upstream to the breakpoint, revealed
no statistically significant difference in expression level
Results of the cytogenetic and genomic characterization of the t(2;11) traslocation breakpoints Figure 1 (see previous page)
Results of the cytogenetic and genomic characterization of the t(2;11) traslocation breakpoints: A) Karyotype of 
the case described in the present study. The black arrows point on derivative chromosomes 2 and 11. B) FISH results obtained 
with fosmids and BAC clones delimiting the breakpoint regions on der(2) and der(11). C) Map of chromosome 2 breakpoint 
region, according to the latest release of the UCSC Genome Browser (March 2006), delimited by BAC clones RP11-1141J14 
(left) and RP11-716G6 (right). RefSeq Genes and CpG islands are represented in blue and green, respectively. Intra-chromo-
somal duplications are reported at the bottom of the figure. Gray, yellow and orange colours refer to the percentage of 
sequence similarity of the duplication (respectively 90–98%, 98–99%, and >99%). D) FISH results obtained using the Chr2-97-1 
Long-PCR product on the bone marrow of the patient. E) Detailed magnified map of the chromosome 2 breakpoint region, 
showing the location of the Chr2-97-1 probe. F) Map of the breakpoint region on chromosome 11. G) and H) Partial chroma-
tograms of the junctions sequences on both derivative chromosomes 11 (G) and 2 (H). Inserted nucleotides [three (CAT) and 
sixteen (GGCGGTATGTCCGTAC) at der(11) and der(2), respectively] at the junctions are underlined in purple.
Table 1: Primers for PCR and sequencing.
Designationa Sequence (5'->3') Positionb Gene
chr2-97-1F AGCCTGTGGTGTGTGTATGAAC chr2:97,380,441–97,380,462 -
chr2-97-1R TGAGTGTAGGTGACTGGTGAGG chr2: 97,391,465–97,391,486 -
hpsgtf-R TGACACCTTCCGCTAGTTCC chr11:18,300,606–18,300,625 -
Hps5-F CCTCCCTGCTTCTTTTTCCA chr11:18,299,339–18,299,358 HPS5
HPS5ex20-3216Fc TGCAGGTCTTGTGGTTTCTG chr11:18,263,475 HPS5
HPS5ex21-3255Rc TCTTCTCTCCAGCTCCAAACA chr11:18,261,979–18,261,999 HPS
HPS5ex1-19Fc TTCACGTTCCGCTCTTAGTG chr11:18,300,260–18,300,279 HPS5
HPS5ex1-96Rc CACATCCAGGGCAGTACCTC chr11:18,300,183–18,300,202 HPS5
HPS5ex1-181F TGGTTACTGGGTCTCCTCTCA chr11:18,300,107–18,300,127 HPS5
HPS5-intr1-F TGTGTTTTGTTCATCCCTGTG chr11:18,300,006–18,300,026 HPS5
DA926692 ex1Fc TCAGTCCCAGTCAGGACACA chr2:97,384,972–97,384,991 DA926692
DA926692 ex1Rc AGAGCCAGAGCAGCAGGAG chr2:97,384,918–97,384,936 DA926692
DA926692 ex2aF CCATCAAGGGAAGCAGATGT chr2:97,384,457–97,384,476 DA926692
DA926692 ex2aR GAGGCACCAGGAGAAGCAT chr2:97,384,418–97,384,436 DA926692
DA926692ex2anewFc CCCACAGTGTTACAAGTCATAACATA chr2:97,384,479–97,384,504 DA926692
DA926692ex2anewRc AGGAAGCTTCATGGCTCCTT chr2:97,384,334–97,384,353 DA926692
Beta-act Fc CTGGAACGGTGAAGGTGACA chr7:5,533,739–5,533,758 ACTB
Beta-act Rc AAGGGACTTCCTGTAACAACGCA chr7:5,533,619–5,533,641 ACTB
CD110063-R CACCAGGAGGCAGACGAG chr2:97,391,951–97,391,968 CD110063
ACTB-F GGCATCGTGATGGACTCCG chr7:5,534,773–5,534,789 ACTB
ACTB-R GCTGGAAGGTGGACAGCGA chr7:5,533,972–5,533,990 ACTB
GTF2H1ex9-1201F AGCAGTCAAAAGGGCGAAAT chr11:18,326,030–18,326,043/18,330,004–18,330,010 GTF2H1
GTF2H1ex10-1272R TTCTTGAGGTTTAGTGCAATCG chr11:18,330,062–18,330,083 GTF2H1
ANKex2-351F CCAACCGGAAATGGTACATC chr2:97,147,558–97,147,577 ANKRD36
ANKex2-451R AGAGTTGCACAAGCCTCCTG chr2:97,147,823–97,147,842 ANKRD36
FAHD2Bex5-829F TGTAGCAGATCCACACAACTTAAA chr2:97,113,730–97,113,742/97,115,163–97,115,171 FAHD2B
FAHD2Bex6-864R GACGACTTCCCCATTCACTC chr2:97,113,695–97,113,714 FAHD2B
KIAA1641ex2-214F AGAAAATGGGATGCAGGATT chr2:97,492,508–97,492,527 KIAA1641
KIAA1641ex2-245R GAAATTGACTTCTCATCTGGTCTAA chr2:97,490,960–97,490,957/chr2:97,492,476–97,492,496 KIAA1641
ZAP70ex11-1678F AGCTACTACACTGCCCGCTCA chr2:97,720,549–97,720,560/97,720,651–97,720,660 ZAP70
ZAP70ex11-1749R CTGCGGCTGGAGAACTTG chr2:97,720,709–97,720,726 ZAP70
a F denotes forward; R denotes reverse;
b Position, at nucleotide level, according to the UCSC database, using the BLAT tool http://genome.ucsc.edu/cgi-bin/hgBlat;
cPrimer used in Real-Time PCR analysis.Molecular Cancer 2008, 7:80 http://www.molecular-cancer.com/content/7/1/80
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compared to controls (Fig, 2B). Interestingly, a primer
pair designed in exon 2 (Table 1), downstream to the
breakpoint, detected expression only in the t(2;11) case.
RT-PCR with the same primer pair revealed a band of 173
pb only in the patient's BM and in the genomic DNA sam-
ple, but neither in the T-ALL controls, nor in normal BM
or PB (Fig. 2C). These results were confirmed by nested
RT-PCR with the primer pair DA926692 ex2a, further val-
idated by the sequencing of PCR products (data not
shown). Purity of all RNA samples was tested using ACTB
primers in PCR experiments (Fig. 2D).
Next, we investigated the expression pattern of
3'DA926692 by RQ-PCR in 21 adult tissues. The results
showed the occurrence of the transcript in 6 of 23 exam-
ined tissues (Fig. 3) [normal BM and PB were already
shown to be negative (Fig. 2C)].
Notably, in silico translation of the sequence correspond-
ing to the 173 bp PCR product showed that it contained a
high density of stop codons resulting in very short ORFs.
We hypothesized that this ncRNA could represent a pre-
cursor of an miRNA, but the miRNA prediction table pro-
duced by miRRim http://mirrim.ncrna.org/TableS1.html
and a sequence similarity search at miRBase http://micro
rna.sanger.ac.uk/sequences/search.shtml showed no sig-
nificant matches (data not shown). Similarly, miRNA pre-
dictions by ProMiR II http://cbit.snu.ac.kr/~ProMiR2/
and miR-abela http://www.mirz.unibas.ch/ did not
retrieve any positive results (data not shown).
Figure 2
Results of the HPS5 and DA926692 gene expression analysis Figure 2
Results of the HPS5 and DA926692 gene expression 
analysis: A) and B) RQ-PCR analyses of HPS5, and 
DA926692 exon1, respectively, in the present case [t(2;11), 
four control childhood T-ALL samples [immunophenotype: 
early (#1,2), thymic (#3), and mature (#4) T-ALL], the mean 
Ct value of the controls (mean), normal BM and PB. A) The 
results showed no statistically significant change in HPS5 
expression level with primers for exon1 (HPS5ex1-
19F+HPS5ex1-96R) and exons 20-21 (HPS5ex20-3216F and 
HPS5ex21-3255R), if compared with the mean Ct value of 
the childhood T-ALL controls. B) The results showed com-
parable DA926692 transcriptional levels, when evaluated 
with exon 1 primers (DA926692ex2F and DA926692ex2R), 
between the patient with t(2;11) and the mean Ct value of 
the controls. C) RT-PCR results obtained with 
DA926692ex2anewF and DA926692ex2anewR (Table 1), 
showing a band of 173 bp only in the patient's bone marrow 
(lane 1) and normal genomic DNA (lane 8). Lanes 2-5 corre-
spond to four control childhood T-ALL bone marrow. Lanes 
6, 7 and 9 are normal bone marrow, normal peripheral 
blood, and blank, respectively. M: 2-Log DNA Ladder (New 
England Biolabs, Milan, Italy). D) Control RT-PCR with ACTB 
primers to check the RNA quality, excluding contamination 
of genomic DNA in the patient's bone marrow RNA.Molecular Cancer 2008, 7:80 http://www.molecular-cancer.com/content/7/1/80
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Finally, we used the Gene Prediction tracks of the UCSC
Genome Browser to discover if DA926692 might be part
of a more complex predicted gene. Notably, the N-SCAN
PASA-EST track showed that DA926692  and the EST
CD110063, located in a double position both proximally
(chr2:97,362,909–97,379,287) and distally (chr2:97,391,
882–97,408,261) to DA926692 (Fig. 1E), may be parts of
the predicted gene chr2.98.005.a (data not shown).
To verify this hypothesis, we checked for chr2.98.005.a
gene expression using the primer combination
DA926692ex2anewF+CD110063-R in the patient's BM
cDNA. No PCR products were recovered.
In conclusion, we describe a t(2;11) translocation in T-
ALL not resulting in any HPS5/DA926692 chimeric tran-
script. The impact on cancer causation of a category of
"unproductive" translocations, such as ETV6 gene fusions,
remains unclear [5]. In such cases, the pathogenetic out-
come does not seem to coincide with the formation of a
chimeric protein, but perhaps with the production of a
truncated form of original proteins (loss of function), or
the deregulation of flanking genes.
Tissue expression pattern of EST DA926692 Figure 3
Tissue expression pattern of EST DA926692: DA926692 expression analysis was performed using cDNA multiple tissue 
(Ambion, Milan, Italy) First Choice Total RNA Survey Panel (Catalog No. AM6000) (adipose, bladder, brain, cervix, esophagus, 
heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, trachea), 
according to the manufacturer's instructions. We have also tested a pool of tonsil cDNA extracted from three normal individ-
uals. The primer combination used was DA926692ex2anew (F+R). The results, evaluated by RQ-PCR, showed positivity of 
spleen, ovary, placenta, thyroid, lung, and colon. Compared with the reference ACTB gene expression levels (data not shown), 
the overall DA926692 expression in the positive tissues was found to be relatively low (2-ΔCt ≤ 1.8 × 10-4). The strongest 
expression was seen in the colon.Molecular Cancer 2008, 7:80 http://www.molecular-cancer.com/content/7/1/80
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Here, the only observed gene expression change consisted
in the ectopic expression of the 3' portion of DA926692 in
the patient's BM (Fig. 2C). One hypothesis is that the jux-
taposition, at a distance of only 196 nt, of this genomic
segment to the CpG island located upstream to both HPS5
and GTF2H1 (chr11:18,300,202–18,300,814) could have
activated its expression in the BM cells of the patient.
DA926692  was isolated from a small intestine cDNA
library, described as similar to Ig kappa chain V-I region
HK103 precursor http://www-bimas.cit.nih.gov/cgi-
bicards/carddisp.pl?gene=LOC643543&search=DA92669
2&suff=txt, but no known function has yet been reported.
Its expression in some human adult tissues (Fig. 3) may
suggest a potential function of this transcript in the posi-
tive samples.
As its function is unclear, it is difficult to speculate on a
possible role of this short ncRNA in T-ALL tumorigenesis.
As the bioinformatic analysis excluded the possibility that
it could behave as a pre-miRNA, we could speculate that
this ncRNA may belong to the class of small RNA (20–300
nt), commonly found as transcriptional and translational
regulators [9,10]. A variety of complex cellular mecha-
nisms such as gene transcription, chromatin structure
dynamics, and others have already been connected to
their function [10]. Furthermore, changes in expression
levels of ncRNAs have been associated with different types
of cancer [9].
In this context, we could speculate that the ectopic expres-
sion of the 3' portion of DA926692 in chilhood T-ALL
could have a pathogenetic role, even if of still unclear sig-
nificance. It is presently unknown, however, if the
described rearrangement represents a primary or a second-
ary genetic aberration at disease onset. Further studies on
similar cases may be extremely important to confirm this
new impact of chromosomal translocation, i.e. activation
of ncRNA in tumors.
Abbreviations
(T-ALL): T-cell Acute Lymphoblastic Leukemia; (TCR): T-
Cell Receptor; (CT): Computed Tomography; (BM): Bone
Marrow; (PB): Peripheral Blood; (FISH): Fluorescence In
Situ Hybridization; (BAC): Bacterial Artificial Chromo-
some; (HPS5): Hermansky-Pudlak syndrome 5 isoform b;
(GTF2H1): general transcription factor IIH, polypeptide 1;
(nt): nucleotide; (RQ-PCR): Real-Time Quantitative PCR;
(ANKRD36): ankyrin repeat domain 36; (FAHD2B):
fumarylacetoacetate hydrolase domain containing;
(KIAA1641): hypothetical protein LOC57730; (ZAP70):
zeta-chain associated protein kinase 70 KDa; (ORFs):
Open Reading Frames; (miRNAs): microRNAs; (ncRNA):
non-coding RNA.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MCG and AL designed research and performed molecular
analyses. FA and IV contributed in clinical data collection
and analysis. SC and AL performed classical cytogenetic
analysis and contributed in the development of the study.
LI performed molecular cytogenetic analysis. PD per-
formed bioinformatic analysis. IP contributed in molecu-
lar data analysis and interpretation of the results. MR and
GB gave final approval to the manuscript. CTS supervised
the study and drafted the manuscript.
Acknowledgements
This work has been supported by AIRC (Associazione Italiana per la Ricerca 
sul Cancro), the MIUR (Ministero dell'Istruzione, dell'Università e della 
Ricerca), and Fondazione Città della Speranza. The authors thank Dr. A. 
Pico, Dr. A. Tornesello, and Dr. E. Giarin for their contribution to the 
study, and Prof. Roscoe Stanyon for language revision of the manuscript.
References
1. Mitelman F, Johansson B, Mertens F: The impact of translocations
and gene fusions on cancer causation.  Nat Rev Cancer 2007,
7:233-245.
2. van Dyck F, Declercq J, Braem CV, van de Ven WJ: PLAG1, the pro-
totype of the PLAG gene family: versatility in tumour devel-
opment (review).  Int J Oncol 2007, 30:765-774.
3. Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC,
Impera L, Lonoce A, Funes S, Macri E, Iuzzolino P, et al.: Upregula-
tion of the SOX5 by promoter swapping with the P2RY8
gene in primary splenic follicular lymphoma.  Leukemia 2007,
21:2221-2225.
4. Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV,
Grundy PE, Leach S, Marra MA, Brooks-Wilson AR, Penninger J,
Sorensen PH: Differential expression of a novel ankyrin con-
taining E3 ubiquitin-protein ligase, Hace1, in sporadic
Wilms' tumor versus normal kidney.  Hum Mol Genet 2004,
13:2061-2074.
5. Panagopoulos I, Strombeck B, Isaksson M, Heldrup J, Olofsson T,
Johansson B: Fusion of ETV6 with an intronic sequence of the
BAZ2A gene in a paediatric pre-B acute lymphoblastic leu-
kaemia with a cryptic chromosome 12 rearrangement.  Br J
Haematol 2006, 133:270-275.
6. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A:
Cytogenetics and molecular genetics of T-cell acute lym-
phoblastic leukemia: from thymocyte to lymphoblast.  Leuke-
mia 2006, 20:1496-1510.
7. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, Velden V van
der, Fischer S, Stanulla M, Basso G, Niggli FK, Schafer BW, et al.: Min-
imal residual disease-directed risk stratification using real-
time quantitative PCR analysis of immunoglobulin and T-cell
receptor gene rearrangements in the international multi-
center trial AIEOP-BFM ALL 2000 for childhood acute lym-
phoblastic leukemia.  Leukemia 2008, 22:771-782.
8. Mitelman F: ISCN. An international system for human cytogenetic nomen-
clature Basel, Switzerland: Karger; 1995. 
9. Costa FF: Non-coding RNAs: lost in translation?  Gene 2007,
386:1-10.
10. Mattick JS, Makunin IV: Non-coding RNA.  Hum Mol Genet 2006,
15(Spec No 1):R17-29.